Nε-(Carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function

Zoltn Wagner, I. Wittmann, Istvan Mazak, Reinhard Schinzel, August Heidland, Rosemarie Kientsch-Engel, J. Nagy

Research output: Article

86 Citations (Scopus)

Abstract

Advanced glycation end products (AGEs) such as Nε-(carboxymethyl)lysine (CML) have been implicated in the development and progression of diabetic nephropathy. The aim of the present study is to investigate AGE levels in patients with type 2 diabetes with special regard to the role of renal impairment. Serum and urine CML levels (using a newly developed enzyme-linked immunosorbent assay), as well as serum AGE-fluorescence, were measured in 109 patients with type 2 diabetes. Patients were divided into groups with normal and impaired renal function. We found elevated serum fluorescent AGE and CML levels, as well as decreased urinary CML excretion rates, in patients with diabetes with renal impairment, but not those with normal renal function. In the presence of impaired renal function, serum CML and fluorescent AGE levels showed a significant inverse relation with creatinine clearance and a significant direct correlation with each other. No relationship could be found between serum AGE levels and parameters of blood glucose control or the presence of the following clinical complications: ischemic heart disease, diabetic retinopathy, and neuropathy. We conclude that the decline in renal function leads to increased serum AGE levels in patients with type 2 diabetes.

Original languageEnglish
Pages (from-to)785-791
Number of pages7
JournalAmerican Journal of Kidney Diseases
Volume38
Issue number4
Publication statusPublished - 2001

Fingerprint

Type 2 Diabetes Mellitus
Kidney
Serum
Advanced Glycosylation End Products
Diabetic Neuropathies
Diabetic Nephropathies
Diabetic Retinopathy
Myocardial Ischemia
Blood Glucose
N(6)-carboxymethyllysine
Creatinine
Fluorescence
Enzyme-Linked Immunosorbent Assay
Urine

ASJC Scopus subject areas

  • Nephrology

Cite this

Nε-(Carboxymethyl)lysine levels in patients with type 2 diabetes : Role of renal function. / Wagner, Zoltn; Wittmann, I.; Mazak, Istvan; Schinzel, Reinhard; Heidland, August; Kientsch-Engel, Rosemarie; Nagy, J.

In: American Journal of Kidney Diseases, Vol. 38, No. 4, 2001, p. 785-791.

Research output: Article

Wagner, Z, Wittmann, I, Mazak, I, Schinzel, R, Heidland, A, Kientsch-Engel, R & Nagy, J 2001, 'Nε-(Carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function', American Journal of Kidney Diseases, vol. 38, no. 4, pp. 785-791.
Wagner, Zoltn ; Wittmann, I. ; Mazak, Istvan ; Schinzel, Reinhard ; Heidland, August ; Kientsch-Engel, Rosemarie ; Nagy, J. / Nε-(Carboxymethyl)lysine levels in patients with type 2 diabetes : Role of renal function. In: American Journal of Kidney Diseases. 2001 ; Vol. 38, No. 4. pp. 785-791.
@article{bf9c6eb5465d4c8cb53b33c30eff5c5c,
title = "Nε-(Carboxymethyl)lysine levels in patients with type 2 diabetes: Role of renal function",
abstract = "Advanced glycation end products (AGEs) such as Nε-(carboxymethyl)lysine (CML) have been implicated in the development and progression of diabetic nephropathy. The aim of the present study is to investigate AGE levels in patients with type 2 diabetes with special regard to the role of renal impairment. Serum and urine CML levels (using a newly developed enzyme-linked immunosorbent assay), as well as serum AGE-fluorescence, were measured in 109 patients with type 2 diabetes. Patients were divided into groups with normal and impaired renal function. We found elevated serum fluorescent AGE and CML levels, as well as decreased urinary CML excretion rates, in patients with diabetes with renal impairment, but not those with normal renal function. In the presence of impaired renal function, serum CML and fluorescent AGE levels showed a significant inverse relation with creatinine clearance and a significant direct correlation with each other. No relationship could be found between serum AGE levels and parameters of blood glucose control or the presence of the following clinical complications: ischemic heart disease, diabetic retinopathy, and neuropathy. We conclude that the decline in renal function leads to increased serum AGE levels in patients with type 2 diabetes.",
keywords = "Advanced glycation end products (AGEs), Carboxymethyllysine, Diabetic nephropathy, Oxidative stress, Renal function",
author = "Zoltn Wagner and I. Wittmann and Istvan Mazak and Reinhard Schinzel and August Heidland and Rosemarie Kientsch-Engel and J. Nagy",
year = "2001",
language = "English",
volume = "38",
pages = "785--791",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Nε-(Carboxymethyl)lysine levels in patients with type 2 diabetes

T2 - Role of renal function

AU - Wagner, Zoltn

AU - Wittmann, I.

AU - Mazak, Istvan

AU - Schinzel, Reinhard

AU - Heidland, August

AU - Kientsch-Engel, Rosemarie

AU - Nagy, J.

PY - 2001

Y1 - 2001

N2 - Advanced glycation end products (AGEs) such as Nε-(carboxymethyl)lysine (CML) have been implicated in the development and progression of diabetic nephropathy. The aim of the present study is to investigate AGE levels in patients with type 2 diabetes with special regard to the role of renal impairment. Serum and urine CML levels (using a newly developed enzyme-linked immunosorbent assay), as well as serum AGE-fluorescence, were measured in 109 patients with type 2 diabetes. Patients were divided into groups with normal and impaired renal function. We found elevated serum fluorescent AGE and CML levels, as well as decreased urinary CML excretion rates, in patients with diabetes with renal impairment, but not those with normal renal function. In the presence of impaired renal function, serum CML and fluorescent AGE levels showed a significant inverse relation with creatinine clearance and a significant direct correlation with each other. No relationship could be found between serum AGE levels and parameters of blood glucose control or the presence of the following clinical complications: ischemic heart disease, diabetic retinopathy, and neuropathy. We conclude that the decline in renal function leads to increased serum AGE levels in patients with type 2 diabetes.

AB - Advanced glycation end products (AGEs) such as Nε-(carboxymethyl)lysine (CML) have been implicated in the development and progression of diabetic nephropathy. The aim of the present study is to investigate AGE levels in patients with type 2 diabetes with special regard to the role of renal impairment. Serum and urine CML levels (using a newly developed enzyme-linked immunosorbent assay), as well as serum AGE-fluorescence, were measured in 109 patients with type 2 diabetes. Patients were divided into groups with normal and impaired renal function. We found elevated serum fluorescent AGE and CML levels, as well as decreased urinary CML excretion rates, in patients with diabetes with renal impairment, but not those with normal renal function. In the presence of impaired renal function, serum CML and fluorescent AGE levels showed a significant inverse relation with creatinine clearance and a significant direct correlation with each other. No relationship could be found between serum AGE levels and parameters of blood glucose control or the presence of the following clinical complications: ischemic heart disease, diabetic retinopathy, and neuropathy. We conclude that the decline in renal function leads to increased serum AGE levels in patients with type 2 diabetes.

KW - Advanced glycation end products (AGEs)

KW - Carboxymethyllysine

KW - Diabetic nephropathy

KW - Oxidative stress

KW - Renal function

UR - http://www.scopus.com/inward/record.url?scp=0034741275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034741275&partnerID=8YFLogxK

M3 - Article

C2 - 11576882

AN - SCOPUS:0034741275

VL - 38

SP - 785

EP - 791

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 4

ER -